Hospira Receives FDA Approval for Azithromycin for Injection

LAKE FOREST, Ill., June 29 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE:
HSP), the world leader in generic injectable pharmaceuticals, today announced
it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg
vial of azithromycin for injection in the ADD-Vantage(R) System. The
anti-infective medication is a generic version of Pfizer's Zithromax(R) for
injection. U.S. sales of generic and name-brand azithromycin for injection
were approximately $40 million in 2008.

ADD-Vantage is a specially-designed, two-part system that does not require
clinicians to use a needle and syringe to mix the drug and the solution. This
reduces the risk of accidental needlesticks, enhances workflow and can result
in less waste due to stability and shelf-life factors.

"Hospira is the first company to offer azithromycin in an advanced drug
delivery system," said Joshua Gordon, vice president, Specialty
Pharmaceuticals, Hospira. "This reinforces Hospira's commitment to healthcare
worker safety, as well as to providing safe and effective generic drugs to
patients."

Hospira's specialty injectable pharmaceuticals (SIP) offering includes
approximately 200 generic injectable drugs in many dosages and formulations.
In addition, many of its products are available in popular differentiated
formats, several of which are proprietary, such as its ADD-Vantage System and
iSecure(R) prefilled syringes. Therapeutic areas include anesthesia,
anti-infectives, analgesics, cardiovascular, oncology, emergency and other
areas. Hospira has approximately 25 generic drugs scheduled to launch in
various regions around the world in 2009 and 2010.

About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness(TM). As the world leader in specialty
generic injectable pharmaceuticals, Hospira offers one of the broadest
portfolios of generic acute-care and oncology injectables, as well as
integrated infusion therapy and medication management solutions. Through its
products, Hospira helps improve the safety, cost and productivity of patient
care. The company is headquartered in Lake Forest, Ill., and has more than
14,000 employees. Learn more at www.hospira.com.

SOURCE Hospira, Inc.

Media, Daniel Rosenberg, +1-224-212-3366, or Financial Community, Karen King,
+1-224-212-2711, both of Hospira, Inc.